Kriya Therapeutics Inc., with dual headquarters in Durham and Palo Alto, Calif., has acquired a gene therapy startup that Kriya says will align with its approach to treating metabolic disease. Kriya is a UF startup licensing various AAV technologies.
Tramontane Therapeutics Inc., a Barcelona, Spain, startup in gene therapy for metabolic and neurodegenerative diseases, is now a wholly owned subsidiary of Kriya. The acquisition will help Kriya develop a one-time intramuscular gene therapy for treating a condition known as NASH, or nonalcoholic steatohepatitis, the company said in a statement. NASH is a more severe form of fatty liver disease.
Tramontane’s science is based on fibroblast growth factor 21 (FGF21), a hormone that regulates metabolism. The company’s lead program is an adeno-associated virus (AAV) vector that expresses the FGF21 protein at steady levels.